

This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

May 7, 2025

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO (Code No. 4576)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Presentation at ARVO2025
(The Association for Research in Vision and Ophthalmology 2025)

D.Western Therapeutics Institute, Inc. (hereafter, “the Company”) would like to announce that the results of the late Phase II clinical trial for “H-1337” were presented orally at The Association for Research in Vision and Ophthalmology 2025 (hereafter, “ARVO”), which is being held in the Salt Lake City, UT, USA from May 4 to May 8, 2025.

ARVO is the world's largest and most prestigious ophthalmology society, with approximately 12,000 members from over 65 countries. It is a forum for the presentation of the latest research in basic and clinical ophthalmology, and there are two types of presentations: oral sessions and poster sessions. Oral sessions are limited to high-quality research presentations or topics of particular interest. This presentation was made in the oral session, and we believe this was because its content attracted attention.

The title of the accepted presentation and the date and time of the presentation was as follows.

Title:

A Phase 2b Randomized, Double-masked, Active-controlled, Dose-response Study of the Safety and Efficacy of H-1337 in Subjects with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension

Date and time of the announcement:

May 6, 2025, 8:30-8:45 (local time)

The results of this study are as announced in the press release “D. Western Therapeutics Institute, Inc. announces topline results from a Phase 2B study of H1337 Ophthalmic Solution for the treatment of open-angle glaucoma and ocular hypertension.” dated November 18, 2024, and show that H-1337 has a significant

intraocular pressure-lowering effect and sufficient tolerability.

Due to this matter, there will be no change to the earnings forecast for the fiscal year ending December 2025.

Through this announcement, the Company will raise its international profile and further promote licensing activities for H-1337.

End

About DWTI:

D. Western Therapeutics Institute, Inc. (DWTI) is a publicly traded company (TSE:4576). The company was founded under the philosophy of “Innovative New Drugs to the World from Japan.” We are engaging in the following Drug Discovery and Development Business with the objective of providing patients with drugs that are more effective and beneficial than the conventional drugs. with a proprietary compound library, primarily focused on inhibitors of protein kinases. Ripasudil, currently marketed in Japan to treat glaucoma, and under investigation for corneal indications, is one of DWTI’s inventions. Other products under development include DW-1002, DW-5LBT, DWR-2206, and DW-1001.

About H-1337

H-1337 is a small molecule with potent inhibition of a number of kinases important in the management of intraocular pressure. The ocular safety and hypotensive efficacy was previously evaluated in a Phase 1/2A study. This was a double-masked, vehicle-controlled, dose-response study of 28 days duration in patients with open-angle glaucoma or ocular hypertension. In this study, H-1337 ophthalmic solution showed clinically and statistically significant ocular hypotensive activity and was well tolerated, with a relatively low incidence of hyperemia (Hartman PJ, Cooke DL, Hsu HH, et al. Phase I / II , Double-Masked, Randomized, Vehicle-Controlled Study of H-1337 Ophthalmic Solution for Glaucoma and Ocular Hypertension. Ophthalmol Glaucoma 2023;6(2):198-205, NCT03452033).